CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome

EMBO Journal

Volumn 26, Issue 7, 2007, Pages 1831-1842

  Zhang, Pei Jing ^a   Zhao, Jie ^a   Li, Hui Yan ^a   Man, Jiang Hong ^a   He, Kun ^a   Zhou, Tao ^a   Pan, Xin ^a   Li, Ai Ling ^a   Gong, Wei Li ^a   Jin, Bao Feng ^a   Xia, Qing ^a   Yu, Ming ^a   Shen, Bei Fen ^a   Zhang, Xue Min ^a  

^a NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

Author keywords

CUEDC2; Interaction; Progesterone receptor; Transactivation; Ubiquitination

Indexed keywords

HORMONE RECEPTOR; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; SMALL INTERFERING RNA; UBIQUITIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CUEDC2 GENE; DEGRADATION KINETICS; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE REPRESSION; GENE TARGETING; GENETIC SCREENING; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; SUMOYLATION; TRANSACTIVATION; TWO HYBRID SYSTEM; UBIQUITINATION;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; LIGANDS; MEMBRANE PROTEINS; MUTANT PROTEINS; PROGESTERONE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PROGESTERONE; TRANS-ACTIVATION (GENETICS); UBIQUITIN;

EID: 34247228197     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7601602     Document Type: Article

References (43)

1. Abdel-Hafiz H, Takimoto GS, Tung L, Horwitz KB (2002) The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J Biol Chem 277: 33950-33956
2. Arnett-Mansfield RL, DeFazio A, Wain G, Jaworski R, Byth K, Mote P, Clarke C (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61: 4576-4582
3. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z (2000) SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 101: 753-762
4. Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E (2003) Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278: 12335-12343
5. Chen B, Mariano J, Tsai YC, Chan AH, Cohen M, Weissman AM (2006) The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site. Proc Natl Acad Sci USA 103: 341-346
6. Clarke CL, Sutherland RL (1990) Progestin regulation of cellular proliferation. Endocr Rev Res 11: 266-301
7. Desterro JM, Rodriguez MS, Hay RT (1998) SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 2: 233-239
8. Donalcison KM, Yin H, Gekakis N, Supek F, Hoazeiro CA (2003) Ubiquitin signals protein trafficking via interaction with a novel ubquitin binding domain in the membrane fusion regulator, Vps9p. Curr Biol 13: 258-262
9. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, Rourke KO, Koeppen H, Dixit VM (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-91
10. Elledge RM, McGuire WL, Osborne CK (1992) Prognostic factors in breast cancer. Semin Oncol 19: 244-253
11. Evans R (1988) The steroid and thyroid hormone receptor super-family. Science 240: 889-895
12. Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141
13. Goh ELK, Zhu T, Leong WY, Lobie PE (2002) c-Cbl is a negative regulator of GH-stimulated STAT5-mediated transcription. Endocrinology 148: 3590-3603
14. Kip1. Mol Endocrinol 145: 706-711
15. Hissom JR, Moore MR (1987) Progestin effects on growth in the human breast cancer cell line T-47D-possible therapeutic implications. Biochem Biophys Res Commun 145: 706-711
16. Horwitz K, Alexander P (1983) In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology 113: 2195-2201
17. Horwitz KB, McGuire WL (1975) Specific progesterone receptors in human breast cancer. Steroids 25: 497-505
18. Jenster G (1998) Coactivators and corepressors as mediators of nuclear receptor function: an update. Mol Cell Biol 143: 1-7
19. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9: 1603-1614
20. Lange CA, Richer JK, Horwitz KB (1999) Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13: 829-836
21. Lange CA, Shen T, Horwitz KB (2000) Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97: 1032-1037
22. Leo C, Chen JD (2000) The SRC family of nuclear receptor coactivators. Gene (Amst) 245: 1-11
23. Maldonado E, Hampsey M, Reinberg D (1999) Repression: targeting the heart of the matter. Cell 99: 455-458
24. Man JH, Li HY, Zhang PJ, Zhou T, He K, Pan X, Liang B, Li AL, Zhao J, Gong WL, Jin BF, Xia Q, Yu M, Shen BF, Zhang XM (2006) PIAS3 induction of PRB sumoylation represses PRB transactivation by destabilizing its retention in the nucleus. Nucleic Acids Res 34: 5552-5566
25. McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW (1999) Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 69: 3-12
26. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F (1998) Activation of the Src/p21ras/Erk pathway by progesterone receptor via crosstalk with estrogen receptor. EMBO J 17: 2008-2018
27. Musgrove EA, Lee CS, Sutherand RL (1991) Progestin both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11: 5032-5043
28. Nancy HI, Tornesi MB (1997) Estradiol up regulates estrogen receptor and progesterone receptor gene expression in specific ovine uterine cells. Biol Reprod 56: 1205-1215
29. Pan X, Li HY, Zhang PJ, Jin BF, Man JH, Tian LF, Su GY, Zhao J, Li WH, Liu H, Gong WL, Zhou T, Zhang XM (2006) Ubc9 interacts with SOX4 and represses its transcriptional activity. Biochem Biophys Res Commun 344: 727-734
30. Ponting CP (2000) Proteins of the endoplasmic-retivulum-associated degradation pathway: domain detection and function prediction. Biochem J 351: 527-535
31. Richer J, Jacobsen B, Manning N, Abel M,Wolf D, Horwitz K (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277: 5209-5218
32. Sartorius C, Groshong S, Miller L, Powell R, Tung L, Takimoto G, Horwitz K (1994a) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54: 3868-3877
33. Sartorius C, Melville M, Hovland A, Tung L, Takimoto G, Horwitz K (1994b) A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 8: 1347-1360
34. Shen T, Horwitz KB, Lange CA (2001) Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 21: 6122-6131
35. Shih SC, Prag G, Francis SA, Sutanto MA, Hurley JH, Hicke L (2003) A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. EMBO J 22: 1273-1281
36. Sicinski P, Weinberg RA (1997) A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia 2: 335-342
37. Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19: 327-339
38. Steffan JS, Pallos J, Rochabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JM (2004) SUMO modification of Huntingtin and Huntington's disease pathology. Science 304: 100-104
39. Tung L, Mohamed M, Hoeffler J, Takimoto G, Horwitz K (1993) Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7: 1256-1265
40. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP (1998) The nuclear corepressors NcoR and SMRTare key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18: 1369-1378
41. Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP (2002) Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. Mol Cell Biol 22: 5451-5466
42. Weigel NL (1996) Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319: 657-667
43. Zhang YX, Beck CA, Poletti A, Clement IV JP, Prendergast P, Yip TT, Hutchens TW, Edwards DP, Weigel NL (1997) Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol 11: 823-832